451 related articles for article (PubMed ID: 33066042)
1. Sphingosine-1-Phosphate Receptor Modulators and Oligodendroglial Cells: Beyond Immunomodulation.
Roggeri A; Schepers M; Tiane A; Rombaut B; van Veggel L; Hellings N; Prickaerts J; Pittaluga A; Vanmierlo T
Int J Mol Sci; 2020 Oct; 21(20):. PubMed ID: 33066042
[TBL] [Abstract][Full Text] [Related]
2. Deconstructing the Pharmacological Contribution of Sphingosine-1 Phosphate Receptors to Mouse Models of Multiple Sclerosis Using the Species Selectivity of Ozanimod, a Dual Modulator of Human Sphingosine 1-Phosphate Receptor Subtypes 1 and 5.
Selkirk JV; Dines KC; Yan YG; Ching N; Dalvie D; Biswas S; Bortolato A; Schkeryantz JM; Lopez C; Ruiz I; Hargreaves R
J Pharmacol Exp Ther; 2021 Dec; 379(3):386-399. PubMed ID: 34535564
[TBL] [Abstract][Full Text] [Related]
3. Fingolimod downregulates brain sphingosine-1-phosphate receptor 1 levels but does not promote remyelination or neuroprotection in the cuprizone model.
Nystad AE; Lereim RR; Wergeland S; Oveland E; Myhr KM; Bø L; Torkildsen Ø
J Neuroimmunol; 2020 Feb; 339():577091. PubMed ID: 31739156
[TBL] [Abstract][Full Text] [Related]
4. Oligodendrocyte progenitor cell recruitment and remyelination in multiple sclerosis: the more, the merrier?
Tepavčević V; Lubetzki C
Brain; 2022 Dec; 145(12):4178-4192. PubMed ID: 36093726
[TBL] [Abstract][Full Text] [Related]
5. Sphingosine 1-phosphate receptor modulators in multiple sclerosis and other conditions.
McGinley MP; Cohen JA
Lancet; 2021 Sep; 398(10306):1184-1194. PubMed ID: 34175020
[TBL] [Abstract][Full Text] [Related]
6. Nudging oligodendrocyte intrinsic signaling to remyelinate and repair: Estrogen receptor ligand effects.
Khalaj AJ; Hasselmann J; Augello C; Moore S; Tiwari-Woodruff SK
J Steroid Biochem Mol Biol; 2016 Jun; 160():43-52. PubMed ID: 26776441
[TBL] [Abstract][Full Text] [Related]
7. Drug-based modulation of endogenous stem cells promotes functional remyelination in vivo.
Najm FJ; Madhavan M; Zaremba A; Shick E; Karl RT; Factor DC; Miller TE; Nevin ZS; Kantor C; Sargent A; Quick KL; Schlatzer DM; Tang H; Papoian R; Brimacombe KR; Shen M; Boxer MB; Jadhav A; Robinson AP; Podojil JR; Miller SD; Miller RH; Tesar PJ
Nature; 2015 Jun; 522(7555):216-20. PubMed ID: 25896324
[TBL] [Abstract][Full Text] [Related]
8. The sphingosine-1-phosphate receptor 1 modulator ponesimod repairs cuprizone-induced demyelination and induces oligodendrocyte differentiation.
Willems E; Schepers M; Piccart E; Wolfs E; Hellings N; Ait-Tihyaty M; Vanmierlo T
FASEB J; 2024 Jan; 38(2):e23413. PubMed ID: 38243760
[TBL] [Abstract][Full Text] [Related]
9. Oligodendroglial lineage cells express nuclear p57kip2 in multiple sclerosis lesions.
Pfeifenbring S; Metz I; Kremer D; Küry P; Hartung HP; Brück W
Glia; 2013 Aug; 61(8):1250-60. PubMed ID: 23828667
[TBL] [Abstract][Full Text] [Related]
10. Oligodendrocytes in Development, Myelin Generation and Beyond.
Kuhn S; Gritti L; Crooks D; Dombrowski Y
Cells; 2019 Nov; 8(11):. PubMed ID: 31726662
[TBL] [Abstract][Full Text] [Related]
11. An update on the use of sphingosine 1-phosphate receptor modulators for the treatment of relapsing multiple sclerosis.
Dumitrescu L; Papathanasiou A; Coclitu C; Garjani A; Evangelou N; Constantinescu CS; Popescu BO; Tanasescu R
Expert Opin Pharmacother; 2023 Mar; 24(4):495-509. PubMed ID: 36946625
[TBL] [Abstract][Full Text] [Related]
12. Targeting CXCR7/ACKR3 as a therapeutic strategy to promote remyelination in the adult central nervous system.
Williams JL; Patel JR; Daniels BP; Klein RS
J Exp Med; 2014 May; 211(5):791-9. PubMed ID: 24733828
[TBL] [Abstract][Full Text] [Related]
13. Visualizing Sphingosine-1-Phosphate Receptor 1(S1P
Hashemi E; Yoseph E; Tsai HC; Moreno M; Yeh LH; Mehta SB; Kono M; Proia R; Han MH
Cell Mol Neurobiol; 2023 Apr; 43(3):1219-1236. PubMed ID: 35917044
[TBL] [Abstract][Full Text] [Related]
14. The response of NG2-expressing oligodendrocyte progenitors to demyelination in MOG-EAE and MS.
Reynolds R; Dawson M; Papadopoulos D; Polito A; Di Bello IC; Pham-Dinh D; Levine J
J Neurocytol; 2002; 31(6-7):523-36. PubMed ID: 14501221
[TBL] [Abstract][Full Text] [Related]
15. Preclinical discovery and development of fingolimod for the treatment of multiple sclerosis.
Volpi C; Orabona C; Macchiarulo A; Bianchi R; Puccetti P; Grohmann U
Expert Opin Drug Discov; 2019 Nov; 14(11):1199-1212. PubMed ID: 31389262
[No Abstract] [Full Text] [Related]
16. Myelin regulatory factor drives remyelination in multiple sclerosis.
Duncan GJ; Plemel JR; Assinck P; Manesh SB; Muir FGW; Hirata R; Berson M; Liu J; Wegner M; Emery B; Moore GRW; Tetzlaff W
Acta Neuropathol; 2017 Sep; 134(3):403-422. PubMed ID: 28631093
[TBL] [Abstract][Full Text] [Related]
17. Sphingosine 1-phosphate Receptor Modulator Therapy for Multiple Sclerosis: Differential Downstream Receptor Signalling and Clinical Profile Effects.
Chun J; Giovannoni G; Hunter SF
Drugs; 2021 Feb; 81(2):207-231. PubMed ID: 33289881
[TBL] [Abstract][Full Text] [Related]
18. Loss of Tuberous Sclerosis Complex1 in Adult Oligodendrocyte Progenitor Cells Enhances Axon Remyelination and Increases Myelin Thickness after a Focal Demyelination.
McLane LE; Bourne JN; Evangelou AV; Khandker L; Macklin WB; Wood TL
J Neurosci; 2017 Aug; 37(31):7534-7546. PubMed ID: 28694334
[TBL] [Abstract][Full Text] [Related]
19. Molecular and neuroimmune pharmacology of S1P receptor modulators and other disease-modifying therapies for multiple sclerosis.
Kihara Y; Chun J
Pharmacol Ther; 2023 Jun; 246():108432. PubMed ID: 37149155
[TBL] [Abstract][Full Text] [Related]
20. Possible regenerative effects of fingolimod (FTY720) in multiple sclerosis disease: An overview on remyelination process.
Yazdi A; Ghasemi-Kasman M; Javan M
J Neurosci Res; 2020 Mar; 98(3):524-536. PubMed ID: 31385341
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
